Acacia Pharma Group plc

The company's financials show resilient growth, with revenue advancing from $0.00 in Q3 2017 to $0.00 in Q4 2018. Gross profit remained healthy with margins at N/A in Q4 2018 compared to N/A in Q3 2017. Operating income hit -$7.40M last quarter, sustaining a consistent N/A margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$6.90M. Net income dropped to -$6.69M, while earnings per share reached -$0.07. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.